Scientists in a recent study said on 25 November 2020 that the COVID-19-causing coronavirus is mutating as it spreads around the world in the pandemic, but none of the mutations currently documented appears to be making it able to spread more rapidly, Reuters news agency reported on Wednesday.
In a study by the research team from Britain's UCL and Oxford University, and from France's Cirad and Université de la Réunion, using a global dataset of virus genomes from 46,723 people with COVID-19 from 99 countries, collected up to July 2020, researchers identified more than 12,700 mutations, or changes, in the SARS-CoV-2 virus.
Lucy van Dorp, a professor at University College London's Genetics Institute and one of the co-lead researchers on the study, was quoted as saying: "Fortunately, we found that none of these mutations are making COVID-19 spread more rapidly," adding however: "We need to remain vigilant and continue monitoring new mutations, particularly as vaccines get rolled out."
Reportedly, viruses are known to mutate all the time, and some, such as flu viruses, change more frequently than others. Most mutations are neutral, but some can be either advantageous or detrimental to the virus, and some can make vaccines against them less effective. When viruses change like this, vaccines against them have to be adapted regularly to ensure they are hitting the right target.
With the SARS-CoV-2 virus, the first vaccines to show efficacy against the disease it causes could get regulatory approval and begin to be used to immunise people before the end of the year.
Francois Balloux, a UCL professor who also worked on the study, said that its findings, for now, posed no threat to COVID-19 vaccine efficacy, but cautioned that the imminent introduction of vaccines could exert new selective pressures on the virus to mutate to try to evade the human immune system.
The mutation study, preliminary findings of which were originally made public in May 2020 as a pre-print before being reviewed by other scientists, was published in full on 25 November 2020 in the peer-reviewed journal Nature Communications.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study